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Background: QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of
the long-acting b2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium
(NVA237) for the treatment of chronic obstructive pulmonary disease (COPD). We investigated
the safety and efficacy of QVA149 over 52 weeks.
Methods: This 52-week, multicenter, double-blind, parallel-group, placebo-controlled study
randomized (2:1) patients with moderate-to-severe COPD to once-daily QVA149 (110 mg inda-
caterol/50 mg glycopyrronium) or placebo delivered via the Breezhaler device. Primary
endpoint was safety and tolerability for treatment-emergent adverse events (AEs). Secondary
endpoints included safety based on vital signs, electrocardiograms (ECGs), laboratory evalua-
tions, and pre-dose forced expiratory volume in 1 s (FEV1).
Results: Of 339 patients randomized, QVA149 [nZ 226], placebo [nZ 113]; 76.9% male, mean
age: 62.6 years, post-bronchodilator FEV1: 57.4% predicted, 83.5% completed study. A smaller
percentage of patients discontinued in the QVA149 group (14.2%) compared with placebo
(21.2%). Overall incidence of AEs was similar in the QVA149 (57.8%) and placebo (56.6%) groups,84 59059.
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Safety and efficacy of QVA149 in COPD patients 1559with most AEs being mild to moderate in severity. The numerical differences in some AEs
observed could be at least in part explained by differences in baseline patient characteristics.
No clinically relevant differences were observed between treatment groups for vital signs or
ECG parameters. The five deaths reported were unrelated to study medication (QVA149,
n Z 4 [1.8%]; placebo, n Z 1 [0.9%]). QVA149 demonstrated rapid and clinically meaningful
bronchodilation sustained over 52 weeks versus placebo.
Conclusion: QVA149 demonstrated a good safety and tolerability profile, providing rapid and
sustained bronchodilation over 52 weeks in patients with moderate-to-severe COPD.
ClinicalTrials.gov identifier: NCT01120717.
ª 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Long-acting inhaled bronchodilators relieve symptoms more
effectively than short-acting bronchodilators and are cen-
tral to the management of patients with chronic obstruc-
tive pulmonary disease (COPD) [1]. However, symptoms of
patients with COPD are often inadequately controlled by
long-acting bronchodilator monotherapy. Hence, current
guidelines/strategy recommend that combining broncho-
dilators of different pharmacological classes may improve
efficacy and decrease the risk of side effects compared
with increasing the dose of a single bronchodilator [1].
Studies have shown that the complementary mechanisms of
action of long-acting b2-agonists (LABAs) and long-acting
muscarinic antagonists (LAMAs) significantly improve bron-
chodilation in patients with COPD compared with respec-
tive monotherapies [2e6]. In the INTRUST I and II studies,
concurrent use of indacaterol and tiotropium once daily
provided superior bronchodilation and reduced hyperinfla-
tion (reflected by increased resting inspiratory capacity)
compared with tiotropium monotherapy [7]. However,
there is currently no fixed-dose combination of a LABA and
a LAMA available for the treatment of COPD.
QVA149, a fixed-dose combination of the LABA indaca-
terol and the LAMA glycopyrronium (NVA237), is a novel,
once-daily dual bronchodilator for the maintenance treat-
ment for COPD. Both monocomponents are approved as
once-daily maintenance treatment for patients with
moderate-to-severe COPD, and the safety and efficacy of
each have been demonstrated in various Phase II and III
studies. Glycopyrronium has demonstrated rapid and sus-
tained improvements in lung function, dyspnea, improve-
ments in health status, exercise endurance and reduced
risk of exacerbations, with improvements similar to those
seen with tiotropium, and an acceptable safety profile
[8e10]. Overall, glycopyrronium was generally well toler-
ated over a treatment period of 52 weeks in comparison
with placebo and tiotropium [10]. Indacaterol has also
demonstrated rapid and sustained bronchodilation, im-
provements in symptom relief for dyspnea and health status
(as evaluated by Transition Dyspnea Index [TDI] and St
George’s Respiratory Questionnaire [SGRQ] scores, respec-
tively), and reduction in rescue medication use and exac-
erbations, with an acceptable safety profile [11e13]. Long-
term safety of indacaterol for up to 52 weeks has been
demonstrated in comparison with placebo and active
comparators such as formoterol and tiotropium [11,14].Recent Phase III studies have demonstrated that QVA149
has an adverse event (AE) profile similar to placebo and
provides significant, sustained, and clinically meaningful
improvements in lung function compared with its mono-
components or tiotropium [15]. QVA149 also improves lung
function more effectively than twice-daily LABA plus
inhaled corticosteroid (ICS; salmeterol/fluticasone) in pa-
tients with moderate-to-severe COPD [16].
The ENLIGHTEN study assessed the safety and efficacy of




The study population comprised men and women 40 years
of age with moderate-to-severe COPD [17] (Stage II or III
according to the GOLD 2008 criteria), a smoking history of
10 pack-years, and a post-bronchodilator forced expira-
tory volume in 1 s (FEV1) of 30% and <80% of the predicted
normal and post-bronchodilator FEV1 to forced vital ca-
pacity (FVC) ratio of <0.70 at screening. Patients were
required to have a total daily symptom score (obtained by
adding the scores for the morning and evening symptoms,
ie, cough, wheezing, sputum production/color, shortness of
breath) of 1 on 4 of the last 7 days prior to randomization.
Key exclusion criteria included COPD exacerbations that
required treatment with antibiotics or oral steroids or
hospitalization in the 6 weeks prior to screening or between
screening and randomization, respiratory tract infection 4
weeks before or during screening, history of asthma and a
clinically significant electrocardiogram (ECG) abnormality.
Further details of inclusion and exclusion criteria are
included in the online supplement [Supplement Table 1].
This study was approved by institutional review boards
and ethics committees at participating centers, and was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice. All patients provided written
informed consent.
Study design and treatment
ENLIGHTEN was a multicenter, randomized, double-blind,
parallel-group, placebo-controlled, 52-week study (Fig. 1)
conducted in academic and clinical research centers in
Figure 1 Study design.
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(ClinicalTrials.gov registration number: NCT01120717). The
study comprised a pre-screening wash-out period (up to 7
days) and a 14-day run-in period during which patients were
assessed for study eligibility and baseline patient diary data
(ie, mean daily total symptom scores were collected). At
the end of the screening period (Visit 3), patients were
randomized (2:1) to once-daily QVA149 110/50 mg or pla-
cebo. Randomization was stratified according to smoking
status (current/ex-smoker). QVA149 and placebo were
administered in the morning between 08:00 and 11:00 h via
the Breezhaler device [18]. No patients received placebo
treatment in isolation at any time during the study: placebo
was included to patients’ established background COPD
therapy, for example, daily ICS. The short-acting broncho-
dilator salbutamol (albuterol) was provided for rescue use
throughout the study. Patients were not permitted to use
short-acting muscarinic antagonists or long-acting bron-
chodilators (LAMAs, LABAs, theophylline) before the
screening period (for at least 7 days for LAMAs and
theophylline; 48 h for LABA and LABA/ICS combinations) or
during the study. However, ICS use was maintained, ie,
patients taking combined LABA/ICS at screening were
transitioned to the equivalent ICS monotherapy.
Endpoints and assessments
The primary endpoint was safety and tolerability of 52-
week treatment with once-daily QVA149 compared with
placebo, in terms of frequency of treatment-emergent AEs.
Secondary endpoints were vital signs, electrocardiograms
(ECGs), laboratory evaluations, and the bronchodilator ef-
fect of QVA149 versus placebo based on the pre-dose FEV1
(mean of the values at 15 and 45 min pre-dose). FVC and
FEV1 measurements at all post-baseline time points were
assessed.
Safety and spirometry assessments (pre-dose and for up
to 1 h post-dose) were recorded when patients returned to
the clinic on Weeks 3, 6, 12, 26, 39, and 52 (Visits 4e9).
Safety assessments included recording all AEs, serious AEs
(SAEs), with their severity and relationship to study drug.
All treatment-emergent AEs were recorded and classifiedas AEs starting on or after the first administration of study
drug but not later than 7 days (30 days in the case of an
SAE) after the end of treatment period. These were coded
using MedDRA (Version 14 or higher). Deaths occurring
during the study in either group were adjudicated by an
external committee. Spirometry measurements were
taken at 45 and 15 min pre-dose and then at 30 and 60 min
post-dose. One spirometry measurement was taken in the
event of discontinuation. Patients were followed up for
safety an additional 30 days after the end of the treatment
period.
Statistical methods and populations for analysis
The sample size calculation was based on pre-trial esti-
mates that 226 patients would be required in the QVA149
group and 113 patients in the placebo group, assuming a
30% discontinuation rate over 12 months, in order to detect
a 1% or 2% AE incidence rate in the QVA149 treatment group
with 80% and 96% probability, respectively. This number
was also adequate to detect a 120-mL difference in pre-
dose mean FEV1 at Week 52 between QVA149 and placebo
(secondary objective), at 5% significance level with an
estimated 94% power. The safety population, comprising all
patients who received at least one dose of study drug and
analyzed according to treatment received, was used for
analysis of all safety endpoints. The primary endpoint of
AEs is presented as the number and percentage of patients
within each treatment group. To control for possible dif-
ferences in exposure between the treatment groups, AEs
were also presented with the total number of events per
patient-year for all AEs together. For QVA149-placebo
comparisons, 95% confidence intervals (CIs) were provided
together with the associated p-values. There were no ad-
justments made for multiplicity and no imputation was
done for the missing safety data. Efficacy endpoints
(spirometry) were analyzed using full analysis set (FAS),
which comprised all randomized patients who received at
least one dose of study drug, analyzed according to
the allocated treatment group. Additional details of the
statistical analysis are provided in the Supplementary
Appendix.
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Patients
Of the 498 patients screened, 339 were randomized to
receive QVA149 (n Z 226) or placebo (n Z 113). Overall,
83.5% of patients completed 52 weeks of study treatment
(Fig. 2). A total of 338 patients were included in the safety
population and the FAS as one patient randomized to the
QVA149 group withdrew consent prior to receiving study
drug due to inability to perform spirometry maneuvers.
Baseline patient demographics and other clinical charac-
teristics were comparable across the two treatment groups,
with the notable exceptions that more patients in the
QVA149 group versus the placebo group had severe COPD
(31.1% vs 18.6%), used ICS at baseline (45.8% vs 38.9%),
respectively, and had a history of myocardial infarction,
stroke, and diabetes mellitus (Table 1). A higher percent-
age of patients discontinued in the placebo group (21.2%)
compared with the QVA149 group (14.2%); the primary
reasons for discontinuation were patients withdrawing
consent and AEs (Fig. 2).
COPD-related concomitant medications were continued
(as background allowable COPD medication) or initiated
after the start of study drug by 60.4% of patients in the
QVA149 group and 51.3% of patients in the placebo group.
The most common medications taken were ICS, which were
used by 44.4% of patients in the QVA149 group and 38.1% of
patients in the placebo group.Long-term safety of QVA149 versus placebo
Treatment-emergent AEs
The overall incidence of AEs was similar for the QVA149
(57.8%) and placebo (56.6%) groups (Table 2), with an AE
rate per 100 patient-years of 232.0 and 222.4, respectively.
The most frequently reported AE was COPD worsening
(QVA149 28.0% vs placebo 25.7%, with an AE rate per 100
patient-years of 50.2 and 50.7, respectively). Cough and
lower respiratory tract infections were slightly more com-
mon for QVA149 compared with placebo, as were pneu-
monia, headache, and pyrexia AEs. Viral upper respiratoryFigure 2 Patientract infection, upper respiratory tract infection, and hy-
pertension AEs were more common in the placebo group
than in the QVA149 group. There were no meaningful dif-
ferences between treatment groups for other AEs as they
occurred in few patients.
The majority of AEs reported in the QVA149 and placebo
groups were moderate (32.9% and 30.1%, respectively) or
mild (12.4% and 17.7%, respectively) in severity. Severe AEs
were reported in 12.4% and 8.8% of patients in the QVA149
and placebo groups, respectively (severe AEs for respira-
tory, thoracic, and mediastinal disorders: 5.3% and 3.5%,
respectively; infections and infestations: 4.0% and 1.8%,
respectively). AEs suspected to be related to study drug
based on investigator assessment were recorded in 5.3% of
patients in the QVA149 group and 7.1% of patients in the
placebo group. Cough was the most commonly reported AE
in the QVA149 group (nZ 7, 3.1%), but was not reported in
the placebo group. Treatment-related AEs were not re-
ported by more than two patients in either group. The
event rate of respiratory-related AEs was not statistically
significantly different for QVA149 compared with placebo
(0.42 vs 0.47, pZ 0.651). Cardio-cerebrovascular (CCV) AEs
were reported in 5.3% of QVA149-treated patients and 2.7%
of placebo-treated patients, with a CCV AE rate per 100
patient-years of 7.7 and 3.1, respectively. The most com-
mon CCV AE was congestive cardiac failure (QVA149 [nZ 3,
1.3%] vs placebo [n Z 0]), followed by supraventricular
extrasystoles (QVA149 [n Z 2, 0.9%] vs placebo [n Z 0]).
SAEs and deaths
The most common SAEs in both treatment groups were COPD
worsening (event rate per 100 patient-years: 6.8 for QVA149
and 5.2 for placebo), followed by pneumonia, which was
only reported in the QVA149 group (nZ 8, event rate: 3.6%,
odds ratio 5.70, p Z 0.074). A post-hoc analysis of serious
pneumonia events, when stratified by COPD severity, did not
provide any conclusive evidence that QVA149 resulted in a
higher incidence of pneumonia SAEs than placebo (event
rate: 3.6%, odds ratio 5.11, p Z 0.101). The rate of
respiratory-related SAEs was not statistically significantly
different between the QVA149 and placebo groups (event
rate: 4.9 vs 1.8, respectively, odds ratioZ 2.85, pZ 0.264).t disposition.
Table 1 Baseline demographics and clinical characteristics (safety population).
QVA149 (n Z 225) Placebo (n Z 113)
Mean (SD) age, years 62.5 (8.81) 62.9 (8.14)
Gender, male, n (%) 174 (77.3) 86 (76.1)
Race, n (%)
Caucasian 178 (79.1) 94 (83.2)
Asian 47 (20.9) 19 (16.8)
Mean (SD) duration of COPD, years 5.82 (5.74) 5.46 (5.10)
COPD severity [17], n (%)
Moderate 154 (68.4) 91 (80.5)
Severe 70 (31.1) 21 (18.6)
Very severe 0 1 (0.9)
COPD exacerbation historya, n (%)
0 154 (68.4) 72 (63.7)
1 56 (24.9) 32 (28.3)
2 15 (6.7) 9 (8.0)
ICS use at baseline, n (%) 103 (45.8) 44 (38.9)
Smoking status, n (%)
Ex-smoker 123 (54.7) 62 (54.9)
Current smoker 102 (45.3) 51 (45.1)
Mean (SD) number of smoking pack-years 36.3 (16.01) 38.1 (15.93)
History of cardiovascular disease, n (%)
Myocardial infarction 9 (4.0) 3 (2.7)
Stroke 6 (2.7) 2 (1.8)
Peripheral arterial disease 13 (5.8) 6 (5.3)
Coronary artery bypass graft 4 (1.8) 0
Type 2 diabetes mellitus, n (%) 28 (12.4) 9 (8.0)
Mean (SD) pre-bronchodilator FEV1, L 1.43 (0.52) 1.49 (0.52)
Mean (SD) post-bronchodilator FEV1, L 1.62 (0.52) 1.69 (0.51)
Mean (SD) post-bronchodilator % predicted FEV1 56.39 (13.27) 59.43 (12.50)
Mean (SD) post-bronchodilator FEV1 reversibility, % 15.74 (14.84) 15.59 (14.53)
Mean (SD) post-bronchodilator FEV1/FVC, % 53.36 (9.43) 55.04 (8.45)
SD Z standard deviation.
a Number of COPD exacerbations in the previous year.
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events, when stratified by COPD severity, showed no sta-
tistically significant treatment difference between the
QVA149 and placebo groups (event rate: 4.9 vs 1.8,
respectively, odds ratio 2.58, p Z 0.345). Besides these
events, no specific SAEs occurred in >1% of patients in
either group. SAEs suspected to be related to study medi-
cation were reported by two patients in the QVA149 group
(two cases of COPD worsening, one case of pneumonia [one
patient reported both pneumonia and COPD worsening]); no
patients in the placebo group had an SAE suspected to be
related to study medication. Adjudicated CCV SAEs were
reported in five patients on QVA149 (2.2%; n Z 4 cardiac
disorders; n Z 1 nervous system disorder) and no patients
on placebo; two of these patients on QVA149 had major
adverse cardiovascular events (MACEs; Table 3). MACEs were
considered to be due to progression of the concomitant
diseases as they were recorded in patients with pre-existing
comorbid conditions. The rate per 100 patient-years for
MACEs was 1.0 in the QVA149 group and 0 in the placebo
group. The incidence of CCV SAEs was not statistically
significantly different between QVA149 and placebo (odds
ratio 3.43, pZ 0.258). In a post-hoc analysis, the incidence
of CCV SAEs, when stratified by COPD severity, was notsignificantly different between the QVA149 and placebo
groups (odds ratio 3.25, p Z 0.284).
Five patients (QVA149 [n Z 4, 1.8%]; placebo [n Z 1,
0.9%]; Table 3) died during the treatment period and
within 30 days of the last treatment; no death was
thought to be related to study medication as determined
by the investigator. The rate of deaths per 100 patient-
years was 1.9 in the QVA149 group and 1.0 in the pla-
cebo group. There was no statistically significant differ-
ence in the time to death between treatment group
(hazard ratio 1.7, 95% CI 0.19, 15.36, p Z 0.638). The
adjudicated causes of deaths in the QVA149 group were
sudden death (one patient), COPD exacerbation with
pneumonia (one patient), and COPD exacerbation without
pneumonia (two patients). The adjudicated cause of
death in the placebo group was a road traffic accident
(one patient).Discontinuation or hospitalization
AEs leading to permanent discontinuation of study drug
were reported in a similar proportion of patients in the
QVA149 (5.8%) and placebo (6.2%) groups; these were most
Table 2 Most frequent AEs (1.0% in the QVA149 treat-
ment group) by preferred term.




Any AE 130 (57.8) 64 (56.6)
COPD worseninga 63 (28.0) 29 (25.7)
Cough 18 (8.0) 7 (6.2)
Viral upper respiratory
tract infection
18 (8.0) 15 (13.3)
Lower respiratory
tract infection
15 (6.7) 4 (3.5)
Upper respiratory
tract infection
12 (5.3) 9 (8.0)
Upper respiratory tract
infection bacterial
11 (4.9) 5 (4.4)
Pyrexia 10 (4.4) 1 (0.9)
Headache 8 (3.6) 3 (2.7)
Pneumonia 8 (3.6) 0
Dizziness 7 (3.1) 1 (0.9)
Sinusitis 7 (3.1) 1 (0.9)
Oropharyngeal pain 6 (2.7) 1 (0.9)
Back pain 5 (2.2) 0
Anxiety 4 (1.8) 0
Hypertension 4 (1.8) 6 (5.3)
Muscle spasms 4 (1.8) 0
Nasopharyngitis 4 (1.8) 0
Urinary tract infection 4 (1.8) 1 (0.9)
Abdominal pain 3 (1.3) 0
Cardiac failure congestive 3 (1.3) 0




Hypercholesterolemia 3 (1.3) 0
Oral candidiasis 3 (1.3) 2 (1.8)
Osteoarthritis 3 (1.3) 2 (1.8)
Rash 3 (1.3) 1 (0.9)
a Data on incidence of COPD exacerbations were combined
with AE data and reported under the preferred term of “COPD
worsening” together with all other events with the same
preferred term.
Table 3 SAEs, deaths and discontinuation of study drug.
QVA149
n Z 225, n (%)
Placebo
n Z 113, n (%)
Patients with any AE(s) 130 (57.8) 64 (56.6)
SAE(s) 37 (16.4) 12 (10.6)
MACE 2 (0.9) 0




Deatha 4 (1.8) 1 (0.9)
Discontinuations due
to AE(s)
13 (5.8) 7 (6.2)
Discontinued due
to SAE(s)
12 (5.3) 3 (2.7)
Discontinued due
to non-SAE(s)
1 (0.4) 4 (3.5)
MACE Z major adverse cardiovascular event.
a Death Z number of patients who died between the first
treatment day and 30 days after the last treatment.
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(nZ 4; 1.8%) in the QVA149 group versus 0.9% and 0% in the
placebo group, respectively. A lower proportion of patients
on QVA149 discontinued due to non-serious AEs compared
with placebo (0.4% vs 3.5%, respectively). Discontinuation
due to a SAE was reported by 12 patients in the QVA149
group (5.3%) and three in the placebo group (2.7%). SAEs
that led to permanent discontinuation of study drug were
COPD worsening (n Z 4), pneumonia (n Z 4), cancer
(n Z 2), upper respiratory tract infection (n Z 1), cardio-
respiratory arrest (nZ 1), pulmonary tuberculosis (nZ 1),
vertigo (n Z 1), and worsening of ischemic heart disorder
(n Z 1).
AEs that led to hospitalization or prolonged hospitali-
zation were reported in 15.1% patients in the QVA149 group
and 8.8% patients in the placebo group, with the most
common cause being COPD worsening (5.3% of patients on
QVA149 and 3.5% of patients on placebo).Additional safety parameters
There were no clinically meaningful differences between
treatment groups or trends for any of the routine hema-
tology, biochemistry, or urinalysis parameters; analysis of
vital signs (pulse rate, systolic and diastolic blood pres-
sure); or serum potassium and blood glucose parameters.
There were no clinically relevant between-treatment dif-
ferences in QTc interval, ventricular rate, RR-interval, PR-
interval, QT-interval, or QRS duration at any time point,
and least square (LS) mean treatment differences were less
than 3 ms. No trend toward prolongation of the QTc interval
was seen in any treatment group.
Efficacy
Spirometry
Pre-dose FEV1 at Week 52 was significantly improved in the
QVA149 group compared with the placebo group, with a
treatment difference of 0.189 L (p < 0.001; Fig. 3). QVA149
provided a significantly greater and clinically meaningful
increase in pre-dose FEV1 from Week 3 to Week 52 (treat-
ment differences in the range of 0.152e0.189 L; p < 0.001
at all time points vs placebo; Fig. 3).
Bronchodilation with QVA149 at 60 min post-dose was
significantly greater than placebo throughout the 52-week
treatment period, with a treatment difference ranging
from 0.200 to 0.286 L (p < 0.001 at all time points; Fig. 4).
QVA149 also improved FVC versus placebo over the 52-
week treatment period, with statistical significance at all
time points (p < 0.001; Fig. 5).
Patient diary data
Daily, daytime, and nighttime symptom scores
Symptom scores improved from baseline significantly more
with QVA149 than placebo; for total daily symptom score
(LS mean: 0.573, pZ 0.011), daytime symptom score (LS
mean: 0.499, p Z 0.030), and nighttime symptom score
Figure 3 Pre-dose FEV1 over 52 weeks.
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treatment, QVA149 was also significantly better than pla-
cebo for percentage of days with “no daytime symptoms”
(QVA149-placebo LS mean: 5.294, p Z 0.012) and per-
centage of “days able to perform usual daily activities”
(QVA149-placebo LS mean: 8.134, p Z 0.028). The per-
centage of nights with “no nighttime awakenings” over 52
weeks was numerically better, although not significantly so
(QVA149-placebo LS mean: 6.319, p Z 0.081).
Rescue medication use
Patients on QVA149 used significantly less rescue medica-
tion compared with placebo (LS mean: 0.726 puffs/day,
p Z 0.002).
Discussion
The ENLIGHTEN study has provided the first detailed anal-
ysis of long-term safety with QVA149 versus placebo, asFigure 4 FEV1 at 60 min pwell as additional data on the long-term bronchodilatory
effects of QVA149 in patients with moderate-to-severe
COPD. QVA149 was well tolerated over the 52 weeks of
treatment, with the overall incidence of AEs being similar
between the QVA149 and placebo groups. Most of the AEs
reported were mild to moderate in severity and occurred in
only a small percentage of patients in both groups. These
data provide further support for the good safety profile for
QVA149, similar to data from previous studies where
QVA149 doses were well tolerated and had an AE rate
similar to placebo or active comparators [15,16]. Moreover,
QVA149 was not associated with any clinically relevant
changes in QTc interval, changes in pulse rate, urinalysis,
routine hematology, biochemistry, or blood pressure. This
supports previous findings where QVA149, even at supra-
therapeutic doses, had demonstrated no clinically relevant
effect on these parameters [19].
The incidences of SAEs seen in this study are not unex-
pected in patients with COPD. Similar frequencies of SAEs
have been observed in other studies with an established
standard of therapy for COPD [20e22]. The numerical
imbalance in the rates of SAEs and deaths between the
QVA149 and placebo groups are likely to be a consequence
of demographic imbalance between the groups. At base-
line, more patients in the QVA149 group had severe COPD;
used ICS; and had a history of myocardial infarction, stroke,
and diabetes mellitus. The higher percentage of patients
using ICS in the QVA149 group may be seen as a marker of
greater disease severity and/or tendency to suffer exac-
erbations. The use of ICS is also a risk factor for the
increased incidence of pneumonia seen in patients in the
QVA149 group [23]. Further, no imbalance in the rates of
SAEs and deaths was observed in either indacaterol or gly-
copyrronium monotherapy programs. The imbalances that
occurred in the current study are inconsistent with other
QVA149 studies and likely a result of the demographic
disparity between the two treatment groups [15,16].
The GOLD 2013 report indicates that as severity of COPD
increases from moderate to severe, hospitalization and
mortality rates can increase [1]. This may explain the
higher frequency of AEs leading to hospitalization in theost-dose over 52 weeks.
Figure 5 FVC at 60 min post-dose over 52 weeks.
Safety and efficacy of QVA149 in COPD patients 1565QVA149 group than in the placebo group. This is further
supported by the background (placebo) rates of SAEs
(deaths, pneumonia, cardiovascular events) seen in this
study, which are lower than that expected in a population
with COPD and in comparison to the SAE rates reported in
long-term COPD studies such as UPLIFT [24] and TORCH
[25,26]. The data may also be confounded by a higher
percentage of patients in the placebo arm discontinuing
treatment, reflecting their deteriorating condition. As a
result, patients continuing in the placebo arm in the pre-
sent study may represent a relatively healthy cohort of
patients with COPD.
The incidence of exacerbations of COPD over 12 months
of treatment was similar in the two treatment groups (6.8%
in the QVA149 group and 5.2% in the placebo group).
However, this study was not powered to detect a difference
in the event rate between groups as the patients with a
history of exacerbations in the past 6 weeks were specif-
ically excluded. As a result, 66.7% of the patients had no
history of exacerbations and were relatively stable at
baseline. This approach was adopted to minimize the effect
of exacerbations on the primary endpoint (treatment-
emergent adverse events) of the study. In a further study,
the SPARK study, where patients with a history of exacer-
bations were included, QVA149 reduced significantly all
exacerbations of COPD compared with glycopyrronium and
tiotropium, along with concomitant significant improve-
ments in lung function and health status [27]. The cardio-
and cerebrovascular profile of QVA149 was similar to pla-
cebo. While there was a numerical difference between the
treatment groups for the adjudicated causes of death, the
actual numbers of fatal AEs were too low to allow for any
meaningful interpretation.
The magnitude of the effect of QVA149 on pre-dose FEV1
relative to placebo is comparable to that seen in other
studies with this combination [15,16], and greater than that
observed with clinically comparable doses of indacaterol or
glycopyrronium monotherapy [8e10,15,16,28,29], suggest-
ing an additive effect when this LABA and LAMA are com-
bined as a fixed dose. Improvements in lung function werealso paralleled by significant improvements in the per-
centage of days with “no daytime symptoms”, the per-
centage of “days able to perform usual daily activities”,
symptoms scores, and reduced use of routine rescue
medication for breakthrough symptoms. In previously re-
ported studies, the potent bronchodilator effect of QVA149
treatment was also paralleled by a greater improvement in
dyspnea [16,30] and health status [27] than other
treatments.
Conclusions
QVA149 demonstrated an overall good safety and tolera-
bility profile over 52 weeks of treatment in patients with
moderate-to-severe COPD. The observed numerical differ-
ences in some AEs and SAEs could be at least in part
explained by differences in baseline characteristics,
although this cannot be firmly established from this study.
QVA149 also demonstrated rapid and sustained bronchodi-
lation with concomitant improvements in patient symptoms
and reduced rescue medication use. These findings
demonstrate the potential of dual bronchodilation with
once-daily QVA149 as a safe and effective maintenance
treatment for patients with moderate-to-severe COPD.
Clinical trial
This study is registered at ClinicalTrials.gov with clinical
trial identifier number NCT01120717.
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